Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
The bradykinin B2 receptor antagonist icatibant has recently become available for treating hereditary angioedema. Our observations demonstrate icatibant to be effective and safe for the treatment of both, abdominal and cutaneous attacks in a practice setting beyond clinical studies.
Krause
Karoline
K
Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany.
Metz
Martin
M
Zuberbier
Torsten
T
Maurer
Marcus
M
Magerl
Markus
M
D000328:Adult; D054179:Angioedemas, Hereditary / Q000188:drug therapy* / Q000473:pathology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D065168:Bradykinin Receptor Antagonists; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D065168:Bradykinin Receptor Antagonists; C065679:icatibant; D001920:Bradykinin